Gide advises the banks’ syndicate on $100 million global offering of Nanobiotix

Gide advises the banks’ syndicate, including Jefferies, TD Cowen and Stifel, as global coordinators and joint bookrunners, on $100 million (corresponding to approximately €86.1 million) global offering of Nanobiotix

The offering consists of a capital increase without preferential subscription rights by way of a public offering of 2,218,467 new shares (including new shares in the form of American Depositary Shares), and 345,099 pre-funded warrants.

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity.

Nanobiotix intends to use the net proceeds from the offering to support the development and advancement of JNJ-1900 (NBTXR3), to advance its Nanoprimer and other platforms and for general corporate purposes.

Gide’s team comprised partner Arnaud Duhamel, counsel Guillaume Monnier, and associate Yasmine Tanji.

The banks’ syndicate was also advised by Cooley LLP on U.S. law matters.

Nanobiotix was advised by Jones Day on French and U.S. law matters.